Drug intelligence / Profile preview

NP-011

Development stage: Phase 1
Lead developer: Nexel
Modality: Recombinant Proteins and Enzymes

Overview

NP-011 is a truncated form of human MFG-E8 recombinant protein, developed by Nexel Co., Ltd. It is being investigated for its anti-fibrotic effects and is targeted towards treating conditions such as liver fibrosis, alcoholic hepatitis, and myocardial infarction. NP-011 acts as an ERK inhibitor.

Other names: Truncated form of human MFG-E8 recombinant protein

Targets

MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on NP-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-011.

Explore the full profile